Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Three-times rejected eye implant finally gets FDA nod for diabetic macular edema

This article was originally published in Clinica

Executive Summary

Illuvien, an intravitreal implant that releases drugs in the back of the eye to treat diabetic macular edema (DME), has finally got the thumbs up from the US FDA, after having been rejected three times already by the agency. Shares of the product’s developers, Alimera and pSivida jumped during after-hours trading on 26 September when they revealed the news and they continued to rally before the markets opened on 29 September. Alimera’s share price rose about 22% in premarket trading on 29 September, while pSivida's stock climbed about 13%.

Topics

UsernamePublicRestriction

Register

MT101958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel